Gyre Therapeutics
GYRE
80 hedge funds and large institutions have $90.2M invested in Gyre Therapeutics in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 18 reducing their positions, and 15 closing their positions.
424% more call options, than puts
Call options by funds: $398K | Put options by funds: $76K
72% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 18
59% more capital invested
Capital invested by funds: $56.5M → $90.2M (+$33.6M)
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
3% more funds holding
Funds holding: 78 → 80 (+2)
0.11% more ownership
Funds ownership: 8.52% → 8.63% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.74M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$859K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$803K |
| 4 |
State Street
Boston,
Massachusetts
|
+$555K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$553K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.33M |
| 2 |
Millennium Management
New York
|
-$1.54M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.3M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$811K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$670K |
GYRE Hedge Fund Activity: Q4 2020 in Review
80 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2020, worth a combined $90.2M — up 59% from $56.5M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GYRE positions and 15 closed out — a net gain of 3 holders — while 31 added to existing stakes and 18 trimmed.
The largest buyer was Verition Fund Management, opening a new position worth an estimated $1.74M. The largest seller was Stonepine Capital Management, cutting an estimated $3.33M.
- 80 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2020, up from 78 in Q3 2020.
- Funds reported $90.2M of Gyre Therapeutics stock for Q4 2020, up 59% quarter-over-quarter.
- 18 funds opened new Gyre Therapeutics positions in Q4 2020 and 15 closed out, a net change of +3 holders.
- The largest Gyre Therapeutics buyer in Q4 2020 was Verition Fund Management, an estimated $1.74M added.
- The largest Gyre Therapeutics seller in Q4 2020 was Stonepine Capital Management, an estimated $3.33M sold.
Based on aggregated 13F filings for Q4 2020.